Sara Nayeem, MD, Principal INVESTING AREA: HEALTHCARE, BIOPHARMACEUTICALS Sara joined NEA's healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEAs investment in 3-V Biosciences. In addition, she assists with management of several of NEA's publicly traded portfolio companies, including Targacept, Inhibitex, and Amicus. Prior to joining NEA, Sara was an Associate with Merrill Lynchs Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biological Sciences from Harvard University.
109AB, Level 100